If tumor vessel normalization, as suggested by our preliminary data, can be confirmed, ITPP might improve the delivery of a range of anticancer compounds, such as oncogene-targeting antibodies (e.g., Cetuximab blocking EGFR may further synergize with the EGF-lowering effects of ITPP) or inhibitors of immune checkpoints. This evidence concerns the gene EGF and neoplasm.